Literature DB >> 23295931

Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Giovanni Piccaro1, Federico Giannoni, Perla Filippini, Alessandro Mustazzolu, Lanfranco Fattorini.   

Abstract

Mycobacterium tuberculosis is exposed to hypoxia and acidity within granulomatous lesions. In this study, an acidic culture model of M. tuberculosis was used to test drug activity against aerobic 5-day-old (A5) and hypoxic 5-, 12-, and 19-day-old (H5, H12, and H19, respectively) bacilli after 7, 14, and 21 days of exposure. In A cultures, CFU and pH rapidly increased, while in H cultures growth stopped and pH increased slightly. Ten drugs were tested: rifampin (R), isoniazid (I), pyrazinamide (Z), ethambutol (E), moxifloxacin (MX), amikacin (AK), metronidazole (MZ), nitazoxanide (NZ), niclosamide (NC), and PA-824 (PA). Rifampin was the most active against A5, H5, H12, and H19 bacilli. Moxifloxacin and AK efficiently killed A5 and H5 cells, I was active mostly against A5 cells, Z was most active against H12 and H19 cells, and E showed low activity. Among nitrocompounds, NZ, NC, and PA were effective against A5, H5, H12, and H19 cells, while MZ was active against H12 and H19 cells. To kill all A and H cells, A5- and H5-active agents R, MX, and AK were used in combination with MZ, NZ, NC, or PA, in comparison with R-I-Z-E, currently used for human therapy. Mycobacterial viability was determined by CFU and a sensitive test in broth (day to positivity, MGIT 960 system). As shown by lack of regrowth in MGIT, the most potent combination was R-MX-AK-PA, which killed all A5, H5, H12, and H19 cells in 14 days. These observations demonstrate the sterilizing effect of drug combinations against cells of different M. tuberculosis stages grown in aerobic and hypoxic acidic conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295931      PMCID: PMC3591868          DOI: 10.1128/AAC.02154-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  The near future: improving the activity of rifamycins and pyrazinamide.

Authors:  D A Mitchison; P B Fourie
Journal:  Tuberculosis (Edinb)       Date:  2010-04-09       Impact factor: 3.131

Review 2.  Acid resistance in Mycobacterium tuberculosis.

Authors:  Omar H Vandal; Carl F Nathan; Sabine Ehrt
Journal:  J Bacteriol       Date:  2009-05-22       Impact factor: 3.490

3.  Activity of drug combinations against dormant Mycobacterium tuberculosis.

Authors:  Perla Filippini; Elisabetta Iona; Giovanni Piccaro; Pascale Peyron; Olivier Neyrolles; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

4.  Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.

Authors:  Philana Ling Lin; Veronique Dartois; Paul J Johnston; Christopher Janssen; Laura Via; Michael B Goodwin; Edwin Klein; Clifton E Barry; Joanne L Flynn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

5.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

Authors:  Frederick A Sirgel; Robin M Warren; Elizabeth M Streicher; Thomas C Victor; Paul D van Helden; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2012-02-22       Impact factor: 5.790

6.  Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.

Authors:  Luiz Pedro S de Carvalho; Gang Lin; Xiuju Jiang; Carl Nathan
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

Review 7.  Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Authors:  Scott G Franzblau; Mary Ann DeGroote; Sang Hyun Cho; Koen Andries; Eric Nuermberger; Ian M Orme; Khisimuzi Mdluli; Iñigo Angulo-Barturen; Thomas Dick; Veronique Dartois; Anne J Lenaerts
Journal:  Tuberculosis (Edinb)       Date:  2012-08-30       Impact factor: 3.131

8.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714

9.  Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum.

Authors:  Natalie J Garton; Simon J Waddell; Anna L Sherratt; Su-Min Lee; Rebecca J Smith; Claire Senner; Jason Hinds; Kumar Rajakumar; Richard A Adegbola; Gurdyal S Besra; Philip D Butcher; Michael R Barer
Journal:  PLoS Med       Date:  2008-04-01       Impact factor: 11.069

10.  Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium.

Authors:  Jasvir Dhillon; Douglas B Lowrie; Denis A Mitchison
Journal:  BMC Infect Dis       Date:  2004-11-17       Impact factor: 3.090

View more
  29 in total

1.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

2.  Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.

Authors:  Robert A Mook; Jiangbo Wang; Xiu-Rong Ren; Minyong Chen; Ivan Spasojevic; Larry S Barak; H Kim Lyerly; Wei Chen
Journal:  Bioorg Med Chem       Date:  2015-08-10       Impact factor: 3.641

3.  Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Authors:  Giovanni Piccaro; Giovanna Poce; Mariangela Biava; Federico Giannoni; Lanfranco Fattorini
Journal:  J Antibiot (Tokyo)       Date:  2015-05-06       Impact factor: 2.649

Review 4.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

5.  Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation.

Authors:  Elisabetta Iona; Manuela Pardini; Alessandro Mustazzolu; Giovanni Piccaro; Roberto Nisini; Lanfranco Fattorini; Federico Giannoni
Journal:  J Microbiol       Date:  2016-08-02       Impact factor: 3.422

6.  Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability.

Authors:  Xiaoyu Fan; Hongmin Li; Xinxin Ding; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2019-04-30       Impact factor: 3.922

7.  Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.

Authors:  Angelo Iacobino; Giovanni Piccaro; Federico Giannoni; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

9.  Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis.

Authors:  Matthew W Carroll; Doosoo Jeon; James M Mountz; Jong Doo Lee; Yeon Joo Jeong; Nadeem Zia; Myungsun Lee; Jongseok Lee; Laura E Via; Soyoung Lee; Seok-Yong Eum; Sung-Joong Lee; Lisa C Goldfeder; Ying Cai; Boyoung Jin; Youngran Kim; Taegwon Oh; Ray Y Chen; Lori E Dodd; Wenjuan Gu; Veronique Dartois; Seung-Kyu Park; Cheon Tae Kim; Clifton E Barry; Sang-Nae Cho
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

10.  Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosis.

Authors:  Giovanni Piccaro; Donatella Pietraforte; Federico Giannoni; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.